Zura Bio (ZURA) Stock Forecast, Price Target & Predictions

ZURA Stock Forecast

Zura Bio stock forecast is as follows: an average price target of $10.00 (represents a 338.60% upside from ZURA’s last price of $2.28) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.

ZURA Price Target

The average price target for Zura Bio (ZURA) is $10.00 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $5.00. This represents a potential 338.60% upside from ZURA's last price of $2.28.

ZURA Analyst Ratings

Buy

According to 15 Wall Street analysts, Zura Bio's rating consensus is 'Buy'. The analyst rating breakdown for ZURA stock is 1 'Strong Buy' (6.67%), 11 'Buy' (73.33%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Zura Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 08, 2024	Yatin Suneja	Guggenheim	$15.00	$4.58	227.51%	557.89%
Sep 05, 2024	Mitchell Kapoor	H.C. Wainwright	$5.00	$3.95	26.58%	119.30%

The latest Zura Bio stock forecast, released on Nov 08, 2024 by Yatin Suneja from Guggenheim, set a price target of $15.00, which represents a 227.51% increase from the stock price at the time of the forecast ($4.58), and a 557.89% increase from ZURA last price ($2.28).

Zura Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	2
Avg Price Target	-	$15.00	$10.00
Last Closing Price	$2.28	$2.28	$2.28
Upside/Downside	-100.00%	557.89%	338.60%

In the current month, the average price target of Zura Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zura Bio's last price of $2.28. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 08, 2024	Guggenheim	Buy	Buy	Hold
Nov 04, 2024	Leerink Partners		Outperform	Initialise
Sep 19, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 05, 2024	H.C. Wainwright		Neutral	Initialise
Jun 12, 2024	Cantor Fitzgerald		Overweight	Initialise
May 03, 2024	Piper Sandler		Overweight	Initialise
Apr 01, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 10, 2023	Societe Generale		Buy	Initialise
Oct 10, 2023	Cowen & Co.		Outperform	Initialise
Oct 10, 2023	Scotiabank		Sector Perform	Initialise
Oct 10, 2023	Compass Point		Neutral	Initialise
Oct 10, 2023	Exane BNP Paribas		Outperform	Initialise
Oct 10, 2023	Daiwa		Buy	Initialise
Oct 10, 2023	BNP Paribas		Overweight	Initialise
Oct 10, 2023	Jefferies		Buy	Initialise
May 24, 2023	Raymond James		Strong Buy	Initialise

Zura Bio's last stock rating was published by Guggenheim on Nov 08, 2024. The company gave ZURA a "Buy" rating, the same as its previous rate.

Zura Bio Financial Forecast

Zura Bio Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Zura Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ZURA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Zura Bio EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict ZURA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Zura Bio's previous annual EBITDA (undefined) of $NaN.

Zura Bio Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-17.47M	$-16.59M	$-14.85M	$-14.85M	$-20.52M	$-17.90M	$-16.30M	$-14.70M	$-13.97M	$-11.48M	$-11.23M
High Forecast	$-17.47M	$-16.59M	$-14.85M	$-14.85M	$-20.52M	$-17.90M	$-16.30M	$-11.94M	$-10.69M	$-11.48M	$-11.23M
Low Forecast	$-17.47M	$-16.59M	$-14.85M	$-14.85M	$-20.52M	$-17.90M	$-16.30M	$-18.38M	$-16.44M	$-11.48M	$-11.23M
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Zura Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ZURA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Zura Bio SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Zura Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ZURA last annual SG&A of $NaN (undefined).

Zura Bio EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.20	$-0.19	$-0.17	$-0.17	$-0.23	$-0.20	$-0.19	$-0.17	$-0.16	$-0.13	$-0.15
High Forecast	$-0.20	$-0.19	$-0.17	$-0.17	$-0.23	$-0.20	$-0.19	$-0.14	$-0.12	$-0.13	$-0.15
Low Forecast	$-0.20	$-0.19	$-0.17	$-0.17	$-0.23	$-0.20	$-0.19	$-0.21	$-0.19	$-0.13	$-0.15
Surprise %	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Zura Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ZURA previous annual EPS of $NaN (undefined).

ZURA Forecast FAQ

Is Zura Bio a good buy?

Yes, according to 15 Wall Street analysts, Zura Bio (ZURA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 11 'Buy' recommendations, accounting for 80.00% of ZURA's total ratings.

What is ZURA's price target?

Zura Bio (ZURA) average price target is $10 with a range of $5 to $15, implying a 338.60% from its last price of $2.28. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Zura Bio stock go up soon?

According to Wall Street analysts' prediction for ZURA stock, the company can go up by 338.60% (from the last price of $2.28 to the average price target of $10), up by 557.89% based on the highest stock price target, and up by 119.30% based on the lowest stock price target.

Can Zura Bio stock reach $3?

ZURA's average twelve months analyst stock price target of $10 supports the claim that Zura Bio can reach $3 in the near future.

What are Zura Bio's analysts' financial forecasts?

Zura Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-69.432M (high $-66.676M, low $-73.107M), average SG&A $0 (high $0, low $0), and average EPS is $-0.795 (high $-0.763, low $-0.837). ZURA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-63.755M (high $-63.755M, low $-63.755M), average SG&A $0 (high $0, low $0), and average EPS is $-0.73 (high $-0.73, low $-0.73).